Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | PDK1 | Q15118 | 1/20 | 1.00 |
| ▸ | PDK2 | Q15119 | 1/20 | 1.00 |
| ▸ | PDK3 | Q15120 | 1/20 | 1.00 |
| ▸ | PDK4 | Q16654 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.98 |
| ▸ | TP53 | P04637 | 1/20 | 0.98 |
| ▸ | MAPT | P10636 | 1/20 | 0.98 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.98 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.79 |
| ▸ | KARS1 | Q15046 | 3/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | RXRA | P19793 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31682257 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1KMT2ATSHRCYP2D6 | |
| SCHEMBL29380336 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1KMT2ATSHRCYP2D6 | |
| SCHEMBL17158674 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1KMT2ATSHRCYP2D6 | |
| SCHEMBL14029315 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1KMT2ATSHRCYP2D6 | |
| SCHEMBL27863 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1KMT2ATSHRCYP2D6 | |
| SCHEMBL27864 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1KMT2ATSHRCYP2D6 | |
| SCHEMBL4943352 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1KMT2ATSHRCYP2D6 | |
| SCHEMBL5933820 | 0.99 | CYP3A4 (0.98) | CYP3A4MEN1KMT2ATSHRCYP2D6 | |
| Hydrochloric Acid SCHEMBL29409504 | 0.99 | CYP3A4 (1.00) | CYP3A4MEN1KMT2ATSHRCYP2D6 | |
| SCHEMBL17453400 | 0.99 | CYP3A4 (0.98) | CYP3A4MEN1KMT2ATSHRCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140322304-A1 | COMPOSITIONS AND METHODS RELATING TO PROLIFERATIVE DISEASES | THE PENN STATE RESEARCH FOUNDATION | 2014-10-30 | — | — | US | claimed |
| US-20120141578-A1 | COMPOSITIONS AND METHODS RELATING TO PROLIFERATIVE DISEASES | THE PENN STATE RESEARCH FOUNDATION (US) | 2012-06-07 | — | — | US | claimed |
| US-20200113907-A1 | PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR GENETIC DISEASE ASSOCIATED WITH SPLICING ABNORMALITIES | KYOTO UNIVERSITY (JP) | 2020-04-16 | — | — | US | disclosed |
| US-9839618-B2 | Compositions and methods relating to proliferative diseases | THE PENN STATE RESEARCH FOUNDATION (US) | 2017-12-12 | — | — | US | disclosed |
| US-20100305068-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140322304-A1 | COMPOSITIONS AND METHODS RELATING TO PROLIFERATIVE DISEASES | PCNA, DERA, TOP2A | CYP3A4 4644/4885MEN1 568/4885KMT2A 2303/4885 |
| US-20100305068-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | GOLT1B, NPC1L1, NPC1 | CYP3A4 4800/4885MEN1 3909/4885KMT2A 4369/4885 |
| US-20120141578-A1 | COMPOSITIONS AND METHODS RELATING TO PROLIFERATIVE DISEASES | PCNA, DERA, TOP2A | CYP3A4 4644/4885MEN1 568/4885KMT2A 2303/4885 |
| US-20200113907-A1 | PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR GENETIC DISEASE ASSOCIATED WITH SPLICING ABNORMALITIES | RBM17, SFPQ, HNRNPAB | CYP3A4 4461/4885MEN1 4003/4885KMT2A 3468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.